-
1
-
-
0142244854
-
Injection site reactions with the HIV-1 fusion inhibitor enfuvirtide
-
Ball RA, Kinchelow T (2003). Injection site reactions with the HIV-1 fusion inhibitor enfuvirtide. J Am Acad Dermatol 49: 826-831.
-
(2003)
J Am Acad Dermatol
, vol.49
, pp. 826-831
-
-
Ball, R.A.1
Kinchelow, T.2
-
2
-
-
0037692990
-
Anti-HIV-1 activity of enfuvirtide (T-20) by inhibition of bystander cell death
-
Barretina J, Blanco J, Armand-Ugon M et al (2003). Anti-HIV-1 activity of enfuvirtide (T-20) by inhibition of bystander cell death. Antivir Ther 8: 155-161.
-
(2003)
Antivir Ther
, vol.8
, pp. 155-161
-
-
Barretina, J.1
Blanco, J.2
Armand-Ugon, M.3
-
3
-
-
0037866607
-
Clinical impact of HIV-related lipodystrophy and metabolic abnormalities on cardiovascular disease
-
Behrens GM, Meyer-Olson D, Stoll M et al (2003). Clinical impact of HIV-related lipodystrophy and metabolic abnormalities on cardiovascular disease. AIDS 17 Suppl 1: S149-S154.
-
(2003)
AIDS
, vol.17
, Issue.SUPPL. 1
-
-
Behrens, G.M.1
Meyer-Olson, D.2
Stoll, M.3
-
4
-
-
0037530225
-
Enfuvirtide access, administration, and patient education
-
Celano SA (2003). Enfuvirtide access, administration, and patient education. Hopkins HIV Rep 15: 1-12.
-
(2003)
Hopkins HIV Rep
, vol.15
, pp. 1-12
-
-
Celano, S.A.1
-
5
-
-
0036315615
-
Long-term treatment with subcutaneous T-20, a fusion inhibitor, in HIV-infected patients: Patient satisfaction and impact on activities of daily living
-
Cohen CJ, Dusek A, Green J et al (2002). Long-term treatment with subcutaneous T-20, a fusion inhibitor, in HIV-infected patients: patient satisfaction and impact on activities of daily living. AIDS Patient Care STDS 16: 327-335.
-
(2002)
AIDS Patient Care STDS
, vol.16
, pp. 327-335
-
-
Cohen, C.J.1
Dusek, A.2
Green, J.3
-
6
-
-
0141620176
-
Effect of highly active antiretroviral therapy on time to acquired immunodeficiency syndrome or death using marginal structural models
-
Cole SR, Hernan MA, Robins JM et al (2003). Effect of highly active antiretroviral therapy on time to acquired immunodeficiency syndrome or death using marginal structural models. Am J Epidemiol 158: 687-694.
-
(2003)
Am J Epidemiol
, vol.158
, pp. 687-694
-
-
Cole, S.R.1
Hernan, M.A.2
Robins, J.M.3
-
7
-
-
0033856458
-
Sensitivity of human immunodeficiency virus type 1 to the fusion inhibitor T-20 is modulated by coreceptor specificity defined by the V3 loop of gp120
-
Derdeyn CA, Decker JM, Sfakianos JN et al (2000). Sensitivity of human immunodeficiency virus type 1 to the fusion inhibitor T-20 is modulated by coreceptor specificity defined by the V3 loop of gp120. J Virol 74: 8358-8367.
-
(2000)
J Virol
, vol.74
, pp. 8358-8367
-
-
Derdeyn, C.A.1
Decker, J.M.2
Sfakianos, J.N.3
-
8
-
-
0642365752
-
European Commission approves Fuzeon following FDA approval - First HIV-fusion inhibitor in fight against HIV
-
European Commission (2003). European Commission approves Fuzeon following FDA approval - first HIV-fusion inhibitor in fight against HIV. Infection 31: 7-8.
-
(2003)
Infection
, vol.31
, pp. 7-8
-
-
-
9
-
-
12144288786
-
Predictive factors of virological response to primary antiretroviral treatment
-
Faucher JF, Challier B, Chirouze C et al (2004). Predictive factors of virological response to primary antiretroviral treatment. Presse Med 33: 310-315.
-
(2004)
Presse Med
, vol.33
, pp. 310-315
-
-
Faucher, J.F.1
Challier, B.2
Chirouze, C.3
-
10
-
-
0042769119
-
Hypertension among HIV patients: Prevalence and relationships to insulin resistance and metabolic syndrome
-
Gazzaruso C, Bruno R, Garzaniti A et al (2003). Hypertension among HIV patients: prevalence and relationships to insulin resistance and metabolic syndrome. J Hypertens 21: 1377-1382.
-
(2003)
J Hypertens
, vol.21
, pp. 1377-1382
-
-
Gazzaruso, C.1
Bruno, R.2
Garzaniti, A.3
-
11
-
-
0035487486
-
T-20 phase III studies underway
-
Giles C (2001). T-20 phase III studies underway. Surviv News (Atlanta Ga) 12: 1-12.
-
(2001)
Surviv News (Atlanta Ga)
, vol.12
, pp. 1-12
-
-
Giles, C.1
-
12
-
-
1142310723
-
Enfuvirtide, a new fusion inhibitor for therapy of human immunodeficiency virus infection
-
Hardy H, Skolnik PR (2004). Enfuvirtide, a new fusion inhibitor for therapy of human immunodeficiency virus infection. Pharmacotherapy 24: 198-211.
-
(2004)
Pharmacotherapy
, vol.24
, pp. 198-211
-
-
Hardy, H.1
Skolnik, P.R.2
-
13
-
-
0038187684
-
Novel therapies based on mechanisms of HIV-1 cell entry
-
Kilby JM, Eron JJ (2003). Novel therapies based on mechanisms of HIV-1 cell entry. N Engl J Med 348: 2228-2238.
-
(2003)
N Engl J Med
, vol.348
, pp. 2228-2238
-
-
Kilby, J.M.1
Eron, J.J.2
-
14
-
-
10744229122
-
A controlled phase II trial assessing three doses of enfuvirtide (T-20) in combination with abacavir, amprenavir, ritonavir and efavirenz in non-nucleoside reverse transcriptase inhibitor-naive HIV-infected adults
-
Lalezari JP, DeJesus E, Northfelt DW et al (2003a). A controlled phase II trial assessing three doses of enfuvirtide (T-20) in combination with abacavir, amprenavir, ritonavir and efavirenz in non-nucleoside reverse transcriptase inhibitor-naive HIV-infected adults. Antivir Ther 8: 279-287.
-
(2003)
Antivir Ther
, vol.8
, pp. 279-287
-
-
Lalezari, J.P.1
DeJesus, E.2
Northfelt, D.W.3
-
15
-
-
0037471311
-
A phase II clinical study of the long-term safety and antiviral activity of enfuvirtide-based antiretroviral therapy
-
Lalezari JP, Eron JJ, Carlson M et al (2003b). A phase II clinical study of the long-term safety and antiviral activity of enfuvirtide-based antiretroviral therapy. AIDS 17: 691-698.
-
(2003)
AIDS
, vol.17
, pp. 691-698
-
-
Lalezari, J.P.1
Eron, J.J.2
Carlson, M.3
-
16
-
-
0042885473
-
Influence of subcutaneous injection site on the steady-state pharmacokinetics of enfuvirtide (T-20) in HIV-1-infected patients
-
Lalezari JP, Patel IH, Zhang X et al (2003e). Influence of subcutaneous injection site on the steady-state pharmacokinetics of enfuvirtide (T-20) in HIV-1-infected patients. J Clin Virol 28: 217-222.
-
(2003)
J Clin Virol
, vol.28
, pp. 217-222
-
-
Lalezari, J.P.1
Patel, I.H.2
Zhang, X.3
-
17
-
-
0036853552
-
T-20: A model for novel anti-HIV drugs in development
-
Laurence J (2002). T-20: a model for novel anti-HIV drugs in development. AIDS Read 12: 469-470.
-
(2002)
AIDS Read
, vol.12
, pp. 469-470
-
-
Laurence, J.1
-
18
-
-
0037849954
-
Efficacy of enfuvirtide in patients infected with drug-resistant HIV-1 in Europe and Australia
-
Lazzarin A, Clotet B, Cooper D et al (2003). Efficacy of enfuvirtide in patients infected with drug-resistant HIV-1 in Europe and Australia. N Engl J Med 348: 2186-2195.
-
(2003)
N Engl J Med
, vol.348
, pp. 2186-2195
-
-
Lazzarin, A.1
Clotet, B.2
Cooper, D.3
-
19
-
-
2142827106
-
Effects of drug resistance mutations L100I and V106A on the binding of pyrrolobenzoxazepinone nonnucleoside inhibitors to the human immunodeficiency virus type 1 reverse transcriptase catalytic complex
-
Locatelli GA, Campiani G, Cancio R et al (2004). Effects of drug resistance mutations L100I and V106A on the binding of pyrrolobenzoxazepinone nonnucleoside inhibitors to the human immunodeficiency virus type 1 reverse transcriptase catalytic complex. Antimicrob Agents Chemother 48: 1570-1580.
-
(2004)
Antimicrob Agents Chemother
, vol.48
, pp. 1570-1580
-
-
Locatelli, G.A.1
Campiani, G.2
Cancio, R.3
-
20
-
-
3543087801
-
Cutaneous injection site reactions to long-term therapy with enfuvirtide
-
Maggi P, Ladisa N, Cinori E et al (2004). Cutaneous injection site reactions to long-term therapy with enfuvirtide. J Antimicrob Chemother.
-
(2004)
J Antimicrob Chemother
-
-
Maggi, P.1
Ladisa, N.2
Cinori, E.3
-
21
-
-
0038162585
-
Decline in the AIDS and death rates in the EuroSIDA study: An observational study
-
Mocroft A, Ledergerber B, Katlama C et al (2003). Decline in the AIDS and death rates in the EuroSIDA study: an observational study. Lancet 362: 22-29.
-
(2003)
Lancet
, vol.362
, pp. 22-29
-
-
Mocroft, A.1
Ledergerber, B.2
Katlama, C.3
-
22
-
-
0037529119
-
Atherosclerosis and HIV in the highly active antiretroviral therapy era: Towards an epidemic of cardiovascular disease?
-
Mooser V (2003). Atherosclerosis and HIV in the highly active antiretroviral therapy era: towards an epidemic of cardiovascular disease? AIDS 17(Suppl. 1): S65-S69.
-
(2003)
AIDS
, vol.17
, Issue.SUPPL. 1
-
-
Mooser, V.1
-
23
-
-
10744233678
-
Differences in durability of treatment with initial PI-based regimens
-
Perez-Elias MJ, Moreno A, Moreno S et al (2003). Differences in durability of treatment with initial PI-based regimens. HIV Clin Trials 4: 391-399.
-
(2003)
HIV Clin Trials
, vol.4
, pp. 391-399
-
-
Perez-Elias, M.J.1
Moreno, A.2
Moreno, S.3
-
24
-
-
0037059049
-
Sensitivity of HIV-1 to entry inhibitors correlates with envelope/coreceptor affinity, receptor density, and fusion kinetics
-
Reeves JD, Gallo SA, Ahmad N et al (2002). Sensitivity of HIV-1 to entry inhibitors correlates with envelope/coreceptor affinity, receptor density, and fusion kinetics. Proc Natl Acad Sci USA 99: 16249-16254.
-
(2002)
Proc Natl Acad Sci USA
, vol.99
, pp. 16249-16254
-
-
Reeves, J.D.1
Gallo, S.A.2
Ahmad, N.3
-
25
-
-
0642340674
-
US FDA approves new class of HIV therapeutics
-
Robertson D (2003). US FDA approves new class of HIV therapeutics. Nat Biotechnol 21: 470-471.
-
(2003)
Nat Biotechnol
, vol.21
, pp. 470-471
-
-
Robertson, D.1
-
26
-
-
0038078724
-
Uncommon mutations at residue positions critical for enfuvirtide (T-20) resistance in enfuvirtide-naive patients infected with subtype B and non-B HIV-1 strains
-
Roman F, Gonzalez D, Lambert C et al (2003). Uncommon mutations at residue positions critical for enfuvirtide (T-20) resistance in enfuvirtide-naive patients infected with subtype B and non-B HIV-1 strains. J Acquir Immune Defic Syndr 33: 134-139.
-
(2003)
J Acquir Immune Defic Syndr
, vol.33
, pp. 134-139
-
-
Roman, F.1
Gonzalez, D.2
Lambert, C.3
-
28
-
-
1842458366
-
Drug-resistant variants that evolve during nonsuppressive therapy persist in HIV-1-infected peripheral blood mononuclear cells after long-term highly active antiretroviral therapy
-
Verhofstede C, Noe A, Demecheleer E et al (2004). Drug-resistant variants that evolve during nonsuppressive therapy persist in HIV-1-infected peripheral blood mononuclear cells after long-term highly active antiretroviral therapy. J Acquir Immune Defic Syndr 35: 473-483.
-
(2004)
J Acquir Immune Defic Syndr
, vol.35
, pp. 473-483
-
-
Verhofstede, C.1
Noe, A.2
Demecheleer, E.3
-
29
-
-
0036090585
-
Emergence of resistant human immunodeficiency virus type 1 in patients receiving fusion inhibitor (T-20) monotherapy
-
Wei X, Decker JM, Liu H et al (2002). Emergence of resistant human immunodeficiency virus type 1 in patients receiving fusion inhibitor (T-20) monotherapy. Antimicrob Agents Chemother 46: 1896-1905.
-
(2002)
Antimicrob Agents Chemother
, vol.46
, pp. 1896-1905
-
-
Wei, X.1
Decker, J.M.2
Liu, H.3
|